Recital 6

(6) There is a need to support critical technologies in the following sectors: digital technologies and deep tech innovation, clean and resource-efficient technologies, and biotechnologies. Deep tech innovation should be understood to be those that have the potential to deliver transformative solutions, rooted in cutting-edge science, technology and engineering, including innovation that combines advances in the physical, biological and digital spheres. Digital technologies should include, in particular, those that contribute to the targets and objectives of the Digital Decade Policy Programme 2030, as well as multi-country projects as defined in Decision (EU) 2022/2481. Clean and resource-efficient technologies should include, in particular, net-zero technologies as defined in the Net-Zero Industry Act. Biotechnologies should be understood to be the application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services, including the technologies referred to in the statistical definition of biotechnology of the Organisation for Economic Cooperation and Development, as well as the Union List of Critical Medicines as referred to in the Commission communication of 24 October 2023 entitled ‘Addressing medicine shortages in the EU’ and their components. Projects recognised as strategic under the Net-Zero Industry Act, where those projects comply with the criteria of resilience and competitiveness defined in the Net-Zero Industry Act, and under the Critical Raw Materials Act should be automatically deemed to contribute to the objectives of this Regulation. Digital technologies and deep tech innovation, clean and resource-efficient technologies and biotechnologies which are the subject of an important project of common European interest (IPCEI) approved by the Commission pursuant to Article 107(3), point (b), of the Treaty of the Functioning of the European Union (TFEU) should be deemed critical, and individual projects within the scope of such an IPCEI should be eligible for funding, in accordance with the rules of the relevant programme, to the extent that the identified funding gap and the eligible costs have not yet been completely covered.

← Recital 5 · All articles · Recital 7 →

Source: EUR-Lex (Cellar) · retrieved 2026-10-13 · Text as adopted (Official Journal); later amendments are not incorporated in this text.